145 related articles for article (PubMed ID: 31339816)
21. Identification and management of latent tuberculosis infection.
Hauck FR; Neese BH; Panchal AS; El-Amin W
Am Fam Physician; 2009 May; 79(10):879-86. PubMed ID: 19496388
[TBL] [Abstract][Full Text] [Related]
22. Moving toward tuberculosis elimination: implementation of statewide targeted tuberculin testing in Tennessee.
Cain KP; Garman KN; Laserson KF; Ferrousier-Davis OP; Miranda AG; Wells CD; Haley CA
Am J Respir Crit Care Med; 2012 Aug; 186(3):273-9. PubMed ID: 22561962
[TBL] [Abstract][Full Text] [Related]
23. A scoping review of cost-effectiveness of screening and treatment for latent tubercolosis infection in migrants from high-incidence countries.
Zammarchi L; Casadei G; Strohmeyer M; Bartalesi F; Liendo C; Matteelli A; Bonati M; Gotuzzo E; Bartoloni A;
BMC Health Serv Res; 2015 Sep; 15():412. PubMed ID: 26399233
[TBL] [Abstract][Full Text] [Related]
24. Prevalence of latent tuberculosis infection in persons with and without human immunodeficiency virus infection using two interferon-gamma release assays and tuberculin skin test in a low human immunodeficiency virus prevalence, intermediate tuberculosis-burden country.
Lin WC; Lin HH; Lee SS; Sy CL; Wu KS; Chen JK; Tsai HC; Chen YS
J Microbiol Immunol Infect; 2016 Oct; 49(5):729-736. PubMed ID: 25442858
[TBL] [Abstract][Full Text] [Related]
25. Self-reported Engagement in Care among U.S. Residents with Latent Tuberculosis Infection: 2011-2012.
Mancuso JD; Miramontes R; Winston CA; Horsburgh CR; Hill AN
Ann Am Thorac Soc; 2021 Oct; 18(10):1669-1676. PubMed ID: 33684324
[No Abstract] [Full Text] [Related]
26. Should all patients undergoing treatment with biologic agents be screened annually for latent tuberculosis infection with an interferon gamma release assay?
Johnson MG; Bialas RW; Hall RP; Stout JE
J Dermatolog Treat; 2016 Aug; 27(4):378-80. PubMed ID: 26652171
[TBL] [Abstract][Full Text] [Related]
27. Latent Tuberculosis in Pregnancy: A Systematic Review.
Malhamé I; Cormier M; Sugarman J; Schwartzman K
PLoS One; 2016; 11(5):e0154825. PubMed ID: 27149116
[TBL] [Abstract][Full Text] [Related]
28. Tuberculosis progression rates in U.S. Immigrants following screening with interferon-gamma release assays.
Blount RJ; Tran MC; Everett CK; Cattamanchi A; Metcalfe JZ; Connor D; Miller CR; Grinsdale J; Higashi J; Nahid P
BMC Public Health; 2016 Aug; 16(1):875. PubMed ID: 27558397
[TBL] [Abstract][Full Text] [Related]
29. Screening of latent tuberculosis infection among health care workers working in Hajj pilgrimage area in Saudi Arabia, using interferon gamma release assay and tuberculin skin test.
Bukhary ZA; Amer SM; Emara MM; Abdalla ME; Ali SA
Ann Saudi Med; 2018; 38(2):90-96. PubMed ID: 29620541
[TBL] [Abstract][Full Text] [Related]
30. Diagnostic potential of interferon-gamma release assay to detect latent tuberculosis infection in kidney transplant recipients.
Edathodu J; Varghese B; Alrajhi AA; Shoukri M; Nazmi A; Elgamal H; Aleid H; Alrabiah F; Ashraff A; Mahmoud I; Al-Hajoj S
Transpl Infect Dis; 2017 Apr; 19(2):. PubMed ID: 28170135
[TBL] [Abstract][Full Text] [Related]
31. Cost-effectiveness of QuantiFERON-TB test vs. tuberculin skin test in the diagnosis of latent tuberculosis infection.
Deuffic-Burban S; Atsou K; Viget N; Melliez H; Bouvet E; Yazdanpanah Y
Int J Tuberc Lung Dis; 2010 Apr; 14(4):471-81. PubMed ID: 20202306
[TBL] [Abstract][Full Text] [Related]
32. Interferon-γ release assays for diagnosis of tuberculosis infection and disease in children.
Starke JR;
Pediatrics; 2014 Dec; 134(6):e1763-73. PubMed ID: 25422024
[TBL] [Abstract][Full Text] [Related]
33. [Usefulness of Quantiferon-TB Gold in Tube® in screening for latent tuberculosis infection in health workers].
Martinez-Lacasa X; Font R; Gonzalez S; Sallent S; Jaen A; Lite J; Cuchi E
Enferm Infecc Microbiol Clin; 2015 Oct; 33(8):525-31. PubMed ID: 25613557
[TBL] [Abstract][Full Text] [Related]
34. Cost-effectiveness of tuberculosis screening for migrant children in a low-incidence country.
Usemann J; Ledergerber M; Fink G; Ritz N
Int J Tuberc Lung Dis; 2019 May; 23(5):579-586. PubMed ID: 31097066
[TBL] [Abstract][Full Text] [Related]
35. Interferon-gamma release assay test characteristics depend upon the prevalence of active tuberculosis.
Davidow AL
Int J Tuberc Lung Dis; 2009 Nov; 13(11):1411-5. PubMed ID: 19861015
[TBL] [Abstract][Full Text] [Related]
36. Care Cascade for targeted tuberculosis testing and linkage to Care in Homeless Populations in the United States: a meta-analysis.
Parriott A; Malekinejad M; Miller AP; Marks SM; Horvath H; Kahn JG
BMC Public Health; 2018 Apr; 18(1):485. PubMed ID: 29650047
[TBL] [Abstract][Full Text] [Related]
37. Comparison of latent tuberculosis infection screening strategies before tumor necrosis factor inhibitor treatment in inflammatory arthritis: IGRA-alone versus combination of TST and IGRA.
Jeong DH; Kang J; Jung YJ; Yoo B; Lee CK; Kim YG; Hong S; Shim TS; Jo KW
PLoS One; 2018; 13(7):e0198756. PubMed ID: 29975703
[TBL] [Abstract][Full Text] [Related]
38. National roll-out of latent tuberculosis testing and treatment for new migrants in England: a retrospective evaluation in a high-incidence area.
Loutet MG; Burman M; Jayasekera N; Trathen D; Dart S; Kunst H; Zenner D
Eur Respir J; 2018 Jan; 51(1):. PubMed ID: 29326327
[TBL] [Abstract][Full Text] [Related]
39. A systematic review on TST and IGRA tests used for diagnosis of LTBI in immigrants.
Campbell JR; Krot J; Elwood K; Cook V; Marra F
Mol Diagn Ther; 2015 Feb; 19(1):9-24. PubMed ID: 25579159
[TBL] [Abstract][Full Text] [Related]
40. Tuberculosis screening prior to anti-tumor necrosis factor therapy among patients with immune-mediated inflammatory diseases in Japan: a longitudinal study using a large-scale health insurance claims database.
Tomio J; Yamana H; Matsui H; Yamashita H; Yoshiyama T; Yasunaga H
Int J Rheum Dis; 2017 Nov; 20(11):1674-1683. PubMed ID: 29076252
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
